Effect of nicorandil on proteinuria in well controlled hypertensive patients

Journal of Hypertension

Volumn 27, Issue 3, 2009, Pages 618-625

  Lee, Tsung Ming ^a   Chang, Nen Chung ^b  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

ATP sensitive potassium channels; Endothelin 1; Hypertension; Proteinuria

Indexed keywords

ENDOTHELIN 1; IMMUNOGLOBULIN G; ISOSORBIDE DINITRATE; NICORANDIL; RETINOL BINDING PROTEIN; VALSARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; KIDNEY TUBULE FUNCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

EID: 67649518831     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32831cbd73     Document Type: Article

References (46)

1. Basi S, Lewis JB. Microalbuminuria as a target to improve cardiovascular and renal outcomes. Am J Kidney Dis 2006; 47:927-946.
2. Weisstuch JM, Dworkin LD. Does essential hypertension cause end-stage renal disease? Kidney Int 1992; 41 (Suppl 36):33-37.
3. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, et al. Renoprotective properties of ACE-inhibition in nondiabetic nephropathies with nonnephrotic proteinuria. Lancet 1999; 354:359-364.
4. The GISEN Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349:1857-1863.
5. Ruilope LM, Alcazar JM, Hernandez E, Moreno F, Martinez MA, Rodicio JL. Does an adequate control of blood pressure protect the kidney in essential hypertension? J Hypertens 1990; 8:525-531.
6. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. Ann Int Med 2001; 135:73-87.
7. Viberti G, Wheeldon NM, MicroAlbuminuria Reduction With ALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106:672-678.
8. Lee TM, Su SF, Tsai CH. Effect of pravastatin on proteinuria in patients with well controlled hypertension. Hypertension 2002; 40:67-73.
9. Douglas K, O'Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006; 145:117-124.
10. + channel. Kidney Int 2002; 61:1739-1749.
11. Tanemoto M, Vanoye CG, Dong K, Welch R, Abe T, Hebert SC, Xu JZ. Rat homolog of sulfonylurea receptor 2B determines glibenclamide sensitivity of ROMK2 in Xenopus laevis oocyte. Am J Physiol Renal Physiol 2000; 278:F659-F666.
12. Yamada M, Kurachi Y. A functional role of the C-terminal 42 amino acids of SUR2A and SUR2B in the physiology and pharmacology of cardiovascular ATP-sensitive K(+) channels. J Mol Cell Cardiol 2005; 39:1-6.
13. Xue H, Zhang YL, Liu GS, Wang H. A new ATP-sensitive potassium channel opener protects the kidney from hypertensive damage in spontaneously hypertensive rats. J Pharmacol Exp Ther 2005; 315:501-509.
14. Eddy A. Role of cellular infiltrates in response to proteinuria. Am J Kidney Dis 2001; 37 (1 Suppl 2):S25-S29.
15. Gomez-Garre D, Largo R, Tejera N, Fortes J, Manzarbeitia F, Egido J. Activation of NF-κB in tubular epithelial cells of rats with intense proteinuria: role of angiotensin II and endothelin-1. Hypertension 2001; 37:1171-1178.
16. Maroni BJ, Steinman TI, Mitch WE. A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int 1985; 27:58-65.
17. Sekiya M,SatoM,Funada J,Ohtani T, AkutsuH, Watanabe K.Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol 2005; 46:63-67.
18. Metcalf P, Baker J, Scragg R, Dryson E, Scott A, Wild C. Microalbuminuria in a middle-aged workforce. Diabetes Care 1993; 16:1485-1493.
19. Rodby RA, Rohde RD, Sharon Z, Pohl MA, Bain RP, Lewis EJ. The urine protein to creatinine ratio as a predictor of 24-h urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group. Am J Kidney Dis 1995; 26:904-909.
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31-41.
21. Lee TM, Su SF, Tsai CH. Estrogen attenuates coronary vasoconstriction after angioplasty: role of endothelin-1. Eur J Clin Invest 2002; 32:141-147.
22. Guy JM, McMurray JR. Urinary retinol binding protein: stability and preanalytical handling of specimens for its measurement. Ann Clin Biochem 1993; 30:77-82.
23. Sasaki T, Kuratya H, Nomura K, Utsunomiya K, Ikeda Y. Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus. Jpn J Med 1990; 29:156-163.
24. + channel. Vasa 2007; 36:175-179.
25. Buter H,Hemmelder MH, Navis G,deJong PE,deZeeuw D.The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13:1682-1685.
26. Perico N, Amuchastegui SC, Colosio V, Sonzogni G, Bertani T, Remuzzi G. Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. J Am Soc Nephrol 1994; 5:1139-1146.
27. Sasaki N, Sato T, Ohler A, O'Rourke B, Marbán E. Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation 2000; 101:439-445.
28. Horinaka S, Kobayashi N, Higashi T, Hara K, Hara S, Matsuoka H. Nicorandil enhances cardiac endothelial nitric oxide synthase expression via activation of adenosine triphosphate-sensitive K channel in rat. J Cardiovasc Pharmacol 2001; 38:200-210.
29. Vaziri ND, Wang XQ. cGMP-mediated negative-feedback regulation of endothelial nitric oxide synthase expression by nitric oxide. Hypertension 1999; 34:1237-1241.
30. Liu Y, Burdon KP, Langefeld CD, Beck SR, Wagenknecht LE, Rich SS, et al. T-786C polymorphism of the endothelial nitric oxide synthase gene is associated with albuminuria in the diabetes heart study. J Am Soc Nephrol 2005; 16:1085-1090.
31. Münzel T, Wenzel P, Daiber A. Do we still need organic nitrates? J Am Coll Cardiol 2007; 49:1296-1298.
32. Cottone S, Mulé G, Nardi E, Lorito MC, Guarneri M, Arsena R, et al. Microalbuminuria and early endothelial activation in essential hypertension. J Hum Hypertens 2007; 21:167-172.
33. Hocher B, Thone-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997; 99:1380-1389.
34. Bang LE, Holm J, Svendsen TL. Retinol-binding protein and transferrin in urine. New markers of renal function in essential hypertension and white coat hypertension? Am J Hypertens 1996; 9:1024-1028.
35. Donnelly R, Elliott HL, Meredith PA, Reid JL. Clinical studies with the potassium channel activator cromakalim in normotensive and hypertensive subjects. J Cardiovasc Pharmacol 1990; 16:790-795.
36. Struijker Boudier HAJ, Messing MWJ, van Essen H. Preferential small arteriolar vasodilatation by the potassium channel opener, BRL 38227, in conscious spontaneously hypertensive rats. Eur J Pharmacol 1992; 218:191-193.
37. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002; 359:1269-1275.
38. Lee TM, Lin MS, Chang NC. Effect of ATP-sensitive potassium channel agonists on ventricular remodeling in healed rat infarcts. J Am Coll Cardiol 2008; 51:1309-1318.
39. Janas J, Sitkiewicz D, Januszewicz A, Szczesniak C, Grenda R, Janas RM. Endothelin-1 inactivating peptidase in the human kidney and urine. J Hypertens 2000; 18:475-483.
40. Jin L, Beswick RA, Yamamoto T, Palmer T, Taylor TA, Pollock JS, et al. Increased reactive oxygen species contributes to kidney injury in mineralocorticoid hypertensive rats. J Physiol Pharmacol 2006; 57:343-357.
41. Mano T, Shinohara R, Nagasaka A, Nakagawa H, Uchimura K, Hayashi R, et al. Scavenging effect of nicorandil on free radicals and lipid peroxide in streptozotocin-induced diabetic rats. Metabolism 2000; 49:427-431.
42. Xu J, Nagata K, Obata K, Ichihara S, Izawa H, Noda A, et al. Nicorandil promotes myocardial capillary and arteriolar growth in the failing heart of Dahl salt-sensitive hypertensive rats. Hypertension 2005; 46: 719-724.
43. Katavetin P, Inagi R, Miyata T, Tanaka T, Sassa R, Ingelfinger JR, et al. Albumin suppresses vascular endothelial growth factor via alteration of hypoxia-inducible factor/hypoxia-responsive element pathway. Biochem Biophys Res Commun 2008; 367:305-310.
44. Hollenberg NK, Parving HH, Viberti G, Remuzzi G, Ritter S, Zelenkofske S, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007; 25:1921-1926.
45. Jones MR, Sealey JE, Laragh JH. Effects of angiotensin receptor blockers on ambulatory plasma renin activity in healthy, normal subjects during unrestricted sodium intake. Am J Hypertens 2007; 20:907-916.
46. Watanabe S, Okura T, Kurata M, Irita J, Manabe S, Miyoshi K, et al. Valsartan reduces serum cystatin C and the renal vascular resistance in patients with essential hypertension. Clin Exp Hypertens 2006; 28:451-461.